Brain diseases are not “one-size-fits-all” - but the industry currently treats them that way. At Neumora, our mission is to transform the treatment and patient outcomes for brain diseases –
with precision.
Our proprietary toolbox of state-of-the-art neural network technologies is built to integrate multiple types of data across genomics, imaging, electroencephalogram (EEG), digital and clinical domains to create Data Biopsy Signatures™ that map the underlying disease mechanisms to Precision Phenotypes™ that identify distinct patient subtypes. Through this approach, we have the ability to develop and match the right therapeutic to the right patient populations for more targeted treatments.
Together, we are committed to creating a new era in modern precision medicine. Brain disease doesn’t wait. And neither will we.
with precision.
Our proprietary toolbox of state-of-the-art neural network technologies is built to integrate multiple types of data across genomics, imaging, electroencephalogram (EEG), digital and clinical domains to create Data Biopsy Signatures™ that map the underlying disease mechanisms to Precision Phenotypes™ that identify distinct patient subtypes. Through this approach, we have the ability to develop and match the right therapeutic to the right patient populations for more targeted treatments.
Together, we are committed to creating a new era in modern precision medicine. Brain disease doesn’t wait. And neither will we.
Location: United States, Massachusetts, Watertown
Employees: 51-200
Total raised: $612M
Founded date: 2020
Investors 8
| Date | Name | Website |
| 08.04.2022 | ARCH Ventu... | archventur... |
| - | F-Prime Ca... | fprimecapi... |
| - | Altitude L... | altitudels... |
| - | re.Mind Ca... | remind.vc |
| - | Catalio Ca... | cataliocap... |
| 10.07.2026 | K2 HealthV... | k2hv.com |
| 20.06.2023 | Premier Pa... | premierpar... |
| - | Newpath Ma... | newpath.pa... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.10.2022 | Series B | $112M | - |
| 07.10.2021 | - | $500M | ARCH Ventu... |
Mentions in press and media 13
| Date | Title | Description |
| 16.06.2026 | Kappa Opioid Antidepressant Navacaprant Goes 0-for-3 in Phase 3: Neumora Cuts 35% of Staff | By Chase Fiorini Published: Jun 16 2026, 13:33 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 06.02.2024 | AI neurotech health company Elemind comes out of stealth with $12 million | The company has developed a wearable that can read individual brainwaves and respond in real-time Right now, the best way to diagnose mental health conditions, such as depression and anxiety, is self-reported data from questionnaires like t... |
| 18.07.2023 | Startup Neumora takes a novel depression drug to Phase 3 | Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial. The drug, a daily pill called navacaprant, led to statistically significant... |
| 24.01.2023 | Q4 Was Digital Health’s Worst Quarter for Funding in 5 Years | In 2020 and 2021, investors were taking risks amid low interest rates and there was a mammoth influx of investment dollars into startups. They were willing to pay more amid high valuations to get a piece of innovative healthcare businesses.... |
| 23.01.2023 | Startups measuring the brain that you need to know | Companies are using biomarkers to diagnose and treat mental illness and other neurological disorders Mental illness is considered the silent pandemic that's been overlooked since the start of COVID. The World Health Organization found the g... |
| 11.10.2022 | Neumora Therapeutics Raises $112M in Series B Financing | Neumora Therapeutics, a Watertown, MA-based clinical-stage biotechnology company, raised $112M in Series B funding. The round was led by Abu Dhabi Growth Fund, Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-P... |
| 21.04.2022 | Embracing an ML-first mindset helps startups accelerate time-to-market and build long-term competitiveness | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today! Of the many fascinating insights I get from worki... |
| 02.03.2022 | Alliance for Artificial Intelligence in Healthcare Elects New Board Leadership for 2022 | “AI will continue to have a demonstrable impact on human health. Having spent the last three years ideating with my fellow charter members to establish AAIH, I’m honored to take the reins and thrilled I get to engage with an incredible team... |
| 07.10.2021 | Neumora Therapeutics Emerges With $500M | WATERTOWN, MA, Neumora Therapeutics announced its launch today with $500 million in equity. >> Click here for more funding data on Neumora Therapeutics >> To export Neumora Therapeutics funding data to PDF and Excel, click h... |
| - | Investors have poured $548 million into neuroscience biotechs this year. Meet the 10 startups that have raised the most cash. | Peter Anastasiou, the CEO of Capsida Biotherapeutics. Capsida Biotherapeutics This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Neuroscience companies have raised more money from VCs in rec... |
Show more